About us
Vipergen is a world leading provider of small molecule drug discovery services based on DNA-encoded library (DEL) technologies.
Vipergen offers to current and future partners to discover hits/leads for their high value targets, using three proprietary 2nd and 3rd generation DEL technologies.
Vipergen team
Allan Beck Christensen
Amaya Alzu Farinas
Andrzej Taranta
Caroline Ryberg
Charlotte Andersen
Frank Sløk
Gustav Stærk
Kristian Klint
Lars Petersen
Leif Kongskov Larsen
Nils Jakob Vest Hansen
Ole Kristensen
Peter Blakskjær
Rico Gerup Petersen
Rozalia Korbut
Tobias Nørby Hansen
Vipergen in brief
-
Vipergen is a small molecule drug discovery company – with focus on the hit/lead finding process -
Vipergen introduces the YoctoReactor® (yR) and Binder Trap Enrichment® (BTE) – 2nd generation DNA-encoded small-molecule library technologies
-
Vipergen introduces the in cell Binder Trap Enrichment® (cBTE) – 3rd generation technology (unique)
-
The yR, BTE and cBTE technology platforms are exclusively owned by Vipergen and secured by strong patent positions
-
The company is privately owned by Gunnar Kjems and Dr. Nils Hansen
-
Board members: Gunnar Kjems (chair) and Dr. Nils Hansen
-
Founded by CEO, Dr. Nils Hansen
-
Founded in 2005
-
Incorporated in Copenhagen, Denmark
-
In 2015-24 >100 deals signed, including with top-5 pharma in both USA, EU and Japan